Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

540P - Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4

Date

16 Sep 2021

Session

ePoster Display

Presenters

David Hong

Citation

Annals of Oncology (2021) 32 (suppl_5): S583-S620. 10.1016/annonc/annonc699

Authors

D.S. Hong1, J.M. Clarke2, A. Asch3, J. Charlson4, T.M. Johanns5, E. Calvo6, V. Boni6, M.J. de Miguel6, V. Moreno Garcia7, D.P. Lawrence8, M.O. Butler9, J. Zugazagoitia10, M.A. Blum Murphy11, P. Kebriaei12, G.R. Blumenschein Jr.13, Q. Lin14, H. Danesi15, E. Norry14

Author affiliations

  • 1 Investigational Cancer Therapeuitcs Department, The University of Texas MD Anderson Cancer Center, 77035 - Houston/US
  • 2 Department Of Medicine, Duke Cancer Center, 27710 - Durham/US
  • 3 Division Of Hematology-oncology, Stephenson Cancer Center, Oklahoma University Health Science Center, 73104 - Oklahoma City/US
  • 4 Cancer Center-froedtert Hospital, Medical College of Wisconsin, 53226 - Milwaukee/US
  • 5 Division Of Medical Oncology, Washington University School of Medicine, 63110 - St Louis/US
  • 6 Centro Integral Oncológico Clara Campal, START Madrid-CIOCC, 28050 - Madrid/ES
  • 7 Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, 28040 - Madrid/ES
  • 8 Center For Melanoma, Massachusetts General Hospital, 02114 - Boston/US
  • 9 Department Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, M5G2M9 - Toronto/CA
  • 10 Oncology Department, Hospital Universitario 12 de Octubre, 28041 - Madrid/ES
  • 11 Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 12 Department Of Stem Cell Transplantation And Cellular Therapy, The University of Texas MD Anderson Cancer Center, 77035 - Houston/US
  • 13 Department Of Thoracic/head And Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 77035 - Houston/US
  • 14 Clinical Development, Adaptimmune, 19112 - Philadelphia/US
  • 15 Clinical Development, Adaptimmune Therapeutics, Philadelphia/US
More

Abstract 540P

Background

The ongoing phase 1 SURPASS trial (NCT04044859) evaluates safety and efficacy of next-generation ADP-A2M4CD8 SPEAR T-cells co-expressing the CD8α co-receptor with the engineered T-cell receptor (TCR) targeting MAGE-A4.

Methods

First-in-human trial in HLA-A*02 positive patients (pts) with advanced cancers expressing MAGE-A4 antigen. T-cells are obtained by apheresis, transduced with a lentiviral vector containing the engineered TCR and CD8α co-receptor, and expanded in vitro. Prior to infusion, pts receive lymphodepletion with fludarabine 30 mg/m2/day for 4 days and cyclophosphamide 600 mg/m2/day for 3 days. The study consists of a modified 3 + 3 dose escalation design with an expansion cohort. Clinical outcomes (safety and efficacy), product attributes (dose, cell phenotype), and biomarkers (tumor antigen expression, T-cell persistence after transfer, serum cytokines) are evaluated.

Results

As of 05 Apr 2021, 18 pts (10 male, 8 female) were treated with ADP-A2M4CD8 (range 1.0 to 6 billion transduced cells). Median age was 63.5 yrs, median H-score was 255 (range 130 to 300), and primary tumor types included ovarian (n=5), esophagogastric junction (n=4), esophageal (n=2), head and neck (n=2), and 1 pt each with myxoid/round cell liposarcoma, melanoma, non small cell lung cancer, synovial sarcoma, and urothelial cancers. Overall, patients tolerated treatment. Most adverse events were consistent with those experienced by cancer patients undergoing lymphodepletion chemotherapy and cellular therapy. Of the 18 pts treated as of the data cut-off, 2 pts were awaiting first scans and one patient had expired. Of the 15 evaluable pts, 13 had evidence of disease control and there were RECIST responses in several solid tumor types. This trial is ongoing with additional pts awaiting treatment and further tumor assessments.

Conclusions

ADP-A2M4CD8 SPEAR T-cells have shown an acceptable safety profile. Emerging efficacy data remain encouraging with the majority of pts experiencing disease control and RECIST responses in several solid tumor types. A full update will be presented at the conference.

Clinical trial identification

NCT04044859.

Editorial acknowledgement

Writing and editorial support was provided by Gabrielle Knafler, of Excel Scientific Solutions (Fairfield, CT, USA).

Legal entity responsible for the study

Adaptimmune.

Funding

Adaptimmune.

Disclosure

D.S. Hong: Financial Interests, Personal, Research Grant: AbbVie; Financial Interests, Personal, Research Grant: Adaptimmune; Financial Interests, Personal, Research Grant: Adlai Nortye; Financial Interests, Personal, Research Grant: Amgen; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Research Grant: Bayer; Financial Interests, Personal, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Daiichi-Sankyo; Financial Interests, Personal, Research Grant: Eisai; Financial Interests, Personal, Research Grant: Eli Lilly; Financial Interests, Personal, Research Grant: EMD Serono; Financial Interests, Personal, Research Grant: Erasca; Financial Interests, Personal, Research Grant: Fate Therapeutics; Financial Interests, Personal, Research Grant: Genentech; Financial Interests, Personal, Research Grant: Genmab; Financial Interests, Personal, Research Grant: GlaxoSmithKline; Financial Interests, Personal, Research Grant: Ignyta; Financial Interests, Personal, Research Grant: Infinity; Financial Interests, Personal, Research Grant: Kite; Financial Interests, Personal, Research Grant: Kyowa; Financial Interests, Personal, Research Grant: LOXO; Financial Interests, Personal, Research Grant: Merck; Financial Interests, Personal, Research Grant: MedImmune; Financial Interests, Personal, Research Grant: Millenium; Financial Interests, Personal, Research Grant: Mirati; Financial Interests, Personal, Research Grant: miRNA; Financial Interests, Personal, Research Grant: Molecular Templates; Financial Interests, Personal, Research Grant: Mologen; Financial Interests, Personal, Research Grant: Navier; Financial Interests, Personal, Research Grant: NCI-CTEP; Financial Interests, Personal, Research Grant: Novartis; Financial Interests, Personal, Research Grant: Numab; Financial Interests, Personal, Research Grant: Pfizer; Financial Interests, Personal, Research Grant: Seattle Genetics; Financial Interests, Personal, Research Grant: Takeda; Financial Interests, Personal, Research Grant: Turning Point Therapeutics; Financial Interests, Personal, Research Grant: Verstatem; Financial Interests, Personal, Research Grant: VM Oncology; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: AACR; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Amgen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: ASCO; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: AstraZeneca; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Bayer; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Celgene; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Eli Lilly; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Genentech; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Genmab; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: GlaxoSmithKline; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Janssen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: LOXO; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: miRNA; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Pfizer; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Philips; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: SITC; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Takeda; Financial Interests, Personal, Ownership Interest: Molecular Match; Financial Interests, Personal, Ownership Interest: OncoResponse; Financial Interests, Personal, Ownership Interest: Presagia Inc; Financial Interests, Personal, Advisory Role: Alpha Insights; Financial Interests, Personal, Advisory Role: Acuta; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Axiom; Financial Interests, Personal, Advisory Role: Adaptimmune; Financial Interests, Personal, Advisory Role: Baxter; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: Boxer Capital; Financial Interests, Personal, Advisory Role: COG; Financial Interests, Personal, Advisory Role: Ecor1; Financial Interests, Personal, Advisory Role: Genentech; Financial Interests, Personal, Advisory Role: GLG; Financial Interests, Personal, Advisory Role: Group H; Financial Interests, Personal, Advisory Role: Guidepoint; Financial Interests, Personal, Advisory Role: HCW Precision; Financial Interests, Personal, Advisory Role: Infinity; Financial Interests, Personal, Advisory Role: Janssen; Financial Interests, Personal, Advisory Role: Merrimack; Financial Interests, Personal, Advisory Role: Medscape; Financial Interests, Personal, Advisory Role: Numab; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Prime Oncology; Financial Interests, Personal, Advisory Role: Seattle Genetics; Financial Interests, Personal, Advisory Role: ST Cube; Financial Interests, Personal, Advisory Role: Takeda; Financial Interests, Personal, Advisory Role: Tavistock; Financial Interests, Personal, Advisory Role: Trieza Therapeutics; Financial Interests, Personal, Advisory Role: WebMD. J.M. Clarke: Financial Interests, Speaker’s Bureau: Merck; Financial Interests, Speaker’s Bureau: AstraZeneca; Financial Interests, Training: BMS; Financial Interests, Other, Consultant: AstraZeneca; Financial Interests, Other, Consultant: Merck; Financial Interests, Other, Consultant: Pfizer; Financial Interests, Other, Consultant: NGM Biopharmaceuticals; Financial Interests, Other, Consultant: Spectrum; Financial Interests, Other, Consultant: Genentech; Financial Interests, Research Grant: Bristol-Myers Squibb; Financial Interests, Research Grant: Genentech; Financial Interests, Research Grant: Spectrum; Financial Interests, Research Grant: Adaptimmune; Financial Interests, Research Grant: Medpacto; Financial Interests, Research Grant: Bayer; Financial Interests, Research Grant: AbbVie; Financial Interests, Research Grant: Moderna; Financial Interests, Research Grant: GlaxoSmithKline; Financial Interests, Research Grant: Array; Financial Interests, Research Grant: AstraZeneca; Financial Interests, Research Grant: Grid Therapeutics; Financial Interests, Research Grant: CBMG; Non-Financial Interests, Member of the Board of Directors: Lung Cancer Initiative of North Carolina. J. Charlson: Financial Interests, Other, Consultant: Deciphera; Financial Interests, Other, Consultant: Adaptimmune; Financial Interests, Advisory Board: Adaptimmune. E. Calvo: Financial Interests, Personal, Advisory Board: Adcendo; Financial Interests, Personal, Advisory Board: Alkermes; Financial Interests, Personal, Advisory Board: Amunix; Financial Interests, Personal, Advisory Board: Anaveon; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Board: MonTa; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Nanobiotix; Financial Interests, Personal, Advisory Board: Nouscom; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Invited Speaker: OncoDNA; Financial Interests, Personal, Invited Speaker: PharmaMar; Financial Interests, Personal, Invited Speaker: Roche/Genentech; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: TargImmune; Financial Interests, Personal, Advisory Board: T-knife; Financial Interests, Personal, Advisory Board: Chugai; Financial Interests, Personal, Other, Director, Clinical Research: START Madrid Group; Financial Interests, Personal, Full or part-time Employment: HM Hospitales Group; Financial Interests, Personal, Full or part-time Employment: START Madrid - CIOCC (Centro Integral Oncológico Clara Campal); Financial Interests, Personal, Ownership Interest: START; Financial Interests, Personal, Ownership Interest: Oncoart Associated; Financial Interests, Personal, Ownership Interest: International Cancer Consultants; Financial Interests, Institutional, Funding: Achilles; Financial Interests, Personal, Other, Steering Committee Member: BeiGene; Financial Interests, Personal, Other, Steering Committee Member: MedSIR; Non-Financial Interests, Personal, Officer, Steering Committee Member: EORTC IDMC; Non-Financial Interests, Personal, Member of the Board of Directors: INTHEOS (Investigational Therapeutics in Oncological Sciences) Foundation; Non-Financial Interests, Personal, Advisory Role: PsiOxus; Non-Financial Interests, Personal, Advisory Role: Amcure; Non-Financial Interests, Personal, Member: ASCO; Non-Financial Interests, Personal, Member: ESMO; Non-Financial Interests, Personal, Member: SEOM; Non-Financial Interests, Personal, Member: EORTC. V. Boni: Financial Interests, Personal, Speaker’s Bureau: Lilly; Financial Interests, Personal, Other, Consultant: Puma; Financial Interests, Personal, Other, Consultant: Cytomx; Financial Interests, Personal, Other, Consultant: Loxo Oncology; Financial Interests, Personal, Other, Consultant: Amunix; Financial Interests, Personal, Other, Consultant: Ideaya; Financial Interests, Institutional, Research Grant: Abbvie; Financial Interests, Institutional, Research Grant: ACEO; Financial Interests, Institutional, Research Grant: Adaptaimmune; Financial Interests, Institutional, Research Grant: Amcure; Financial Interests, Institutional, Research Grant: AMGEN; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Research Grant: Cytomx; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Institutional, Research Grant: Genentech/Roche; Financial Interests, Institutional, Research Grant: H3; Financial Interests, Institutional, Research Grant: Incyte; Financial Interests, Institutional, Research Grant: Janssen; Financial Interests, Institutional, Research Grant: Kura; Financial Interests, Institutional, Research Grant: Lilly; Financial Interests, Institutional, Research Grant: Loxo; Financial Interests, Institutional, Research Grant: Nektar; Financial Interests, Institutional, Research Grant: Macrogenics; Financial Interests, Institutional, Research Grant: Menarini; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Research Grant: Merus; Financial Interests, Institutional, Research Grant: Nanobiotix; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: PharmaMar; Financial Interests, Institutional, Research Grant: Principia; Financial Interests, Institutional, Research Grant: PUMA; Financial Interests, Institutional, Research Grant: Sanofi; Financial Interests, Institutional, Research Grant: Taiho; Financial Interests, Institutional, Research Grant: Tesaro; Financial Interests, Institutional, Research Grant: BeiGene; Financial Interests, Institutional, Research Grant: Transgene; Financial Interests, Institutional, Research Grant: Takeda; Financial Interests, Institutional, Research Grant: Incyte; Financial Interests, Institutional, Research Grant: Innovio; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: PsiOxus; Financial Interests, Institutional, Research Grant: Seattle Genetics; Financial Interests, Institutional, Research Grant: Mersana; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Institutional, Research Grant: Daiichi; Financial Interests, Institutional, Research Grant: Astellas; Financial Interests, Institutional, Research Grant: ORCA; Financial Interests, Institutional, Research Grant: Boston Therapeutics; Financial Interests, Institutional, Research Grant: Dynavax; Financial Interests, Institutional, Research Grant: DebioPharm; Financial Interests, Institutional, Research Grant: Boehringen Ingelheim; Financial Interests, Institutional, Research Grant: Regeneron; Financial Interests, Institutional, Research Grant: Millenium; Financial Interests, Institutional, Research Grant: Synthon; Financial Interests, Institutional, Research Grant: Spectrum; Financial Interests, Institutional, Research Grant: Rigontec; Financial Interests, Institutional, Research Grant: Zenith; Financial Interests, Personal, Member of the Board of Directors: Puma; Financial Interests, Personal, Member of the Board of Directors: Cytomx; Financial Interests, Personal, Member of the Board of Directors: Ideaya. J. Zugazagoitia: Financial Interests, Speaker’s Bureau: BMS; Financial Interests, Speaker’s Bureau: Roche; Financial Interests, Speaker’s Bureau: AstraZeneca; Financial Interests, Speaker’s Bureau: Pfizer; Financial Interests, Speaker’s Bureau: NanoString; Financial Interests, Research Grant: AstraZeneca. G.R. Blumenschein Jr.: Financial Interests, Personal, Research Grant: Amgen, Bayer, Adaptimmune, Elelixis, Daiichi Sankyo, GlaxoSmithKline, Immatics, Immunocore, Incyte, Kite Pharma, Macrogenics, Torque, AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, MedImmune, Merck, Novartis, Roche, Xcovery, Tmunity Therapeutics; Financial Interests, Personal, Other, Consulting Fees: Abbvie, Adicet, Amgen, Ariad, Bayer, Clovis Oncology, AstraZeneca, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Instil Bio, Genentech, Gilead, Lilly, Janssen, MedImmune, Merck, Novartis, Roche, Tyme Oncology, Xcovery, Virogin Biotech; Financial Interests, Personal, Other, Participation on a Data Safety Monitoring Board or Advisory Board: Virogin Biotech, Maverick therapeutics; Financial Interests, Personal, Stocks/Shares: Virogin Biotech; Non-Financial Interests, Personal, Other, Immediate family member employment: Johnson & Johnson/Janssen; Financial Interests, Personal, Research Grant: Regeneron, Beigene, Repertoire Immune Medicines, Verastem; Financial Interests, Personal, Other, Consulting Fees: Maverick Therapeutics. Q. Lin: Financial Interests, Personal, Full or part-time Employment: Adaptimmune. H. Danesi: Financial Interests, Personal, Full or part-time Employment: Adaptimmune. E. Norry: Financial Interests, Full or part-time Employment: Adaptimmune. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings